Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

Key Points

Assess the escalating global burden, epidemiological trends, and healthcare economic impacts of MASLD and MASH from a payor and clinical management perspective.
Registered clinical trial protocol under identifier NCT06309992.
Evaluation of disease burden, progression mechanisms, and therapeutic reimbursement dynamics across patient populations with MASLD and MASH.
Highlights the surging global prevalence of metabolic steatotic liver diseases and their progression toward severe fibrotic stages.
Identifies substantial healthcare economic strain and resource utilization demands facing public and private payors as novel therapies emerge.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Evaluates clinical outcomes and healthcare burdens in patients with MASLD and MASH, highlighting expanding clinical demand and payer challenges.

Nct06309992.

No takes yet. Share an insight, caveat, or question.

Younossi et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share